Instrument Inactif

Communiqués SENN AB Nasdaq Stockholm

Actions

SE0010219626

Recherche biotechnologique et médicale

Communiqués

09/06	SenzaGen’s subsidiary receives two orders within non-animal testing with a total value of SEK 2.4 million	AQ
05/06	EU presents roadmap to phase out animal testing – strengthens SenzaGen’s long-term market potential	AQ
12/05	Report from AGM of SenzaGen AB on 12 May 2026	AQ
12/05	SenzaGen’s interim report January–March 2026 \| 10% sales growth alongside increased attention to non-animal methods	AQ
05/05	Invitation to the presentation of SenzaGen's January-March 2026 interim report	AQ
21/04	SenzaGen’s Annual Report 2025 published	AQ
15/04	SenzaGen’s subsidiary receives strategically important order	AQ
08/04	NOTICE OF ANNUAL GENERAL MEETING OF SENZAGEN AB (Publ)	AQ
30/03	SenzaGen wins new global cosmetics group as customer	AQ
17/03	SenzaGen to present strong GARD®skin data at the world’s largest toxicology conference together with leading industry partners	AQ
10/03	Growing interest in non-animal respiratory allergy testing – GARD®air data presented by industry leaders	AQ
13/02	SenzaGen carries out a directed issue of approximately SEK 17.5 million to the institutional investor Eiffel Investment Group	AQ
13/02	SenzaGen’s Year-End Report 2025 \| SenzaGen closes the year with continued strong GARD® sales	AQ
06/02	Invitation to the presentation of SenzaGen's year-end report 2025	AQ
16/12	SenzaGen further strengthens US market position with 1.5 MSEK order from global chemical industry leader	AQ
20/11	SenzaGen opens expanded laboratory facilities to strengthen capacity in line with 2030 growth plan	AQ
18/11	UK signals shift to non-animal testing – new opportunities for SenzaGen	AQ
12/11	SenzaGen secures order worth SEK 2.5 million from leading global tech company	AQ
10/11	SenzaGen presents growth plan and strategic priorities at Capital Markets Day	AQ
05/11	SenzaGen’s interim report January–September 2025 \| Growth and break-even in Q3	AQ
29/10/25	Invitation to the presentation of SenzaGen's Q3 2025 interim report	AQ
03/10/25	SenzaGen secures orders of SEK 1.3 million from a US-based world-leading chemical company	AQ
18/09/25	SenzaGen invites to Capital Markets Day in Stockholm on November 10, 2025	AQ
22/08/25	SenzaGen secures new follow-up order worth approx. 1.0 MSEK for GARD® from a global leading U.S. pharmaceutical company	AQ
20/08/25	SenzaGen’s interim report January–June 2025 \| Strong order intake and expanded OECD approval for GARD®skin	AQ